While no RET-selective inhibitors are currently FDA approved, numerous multikinase inhibitors (vandetanib, lenvatinib, sunitinib) have been studied in patients with RET-rearranged lung cancer, but outcomes were modest when compared to the efficacy of TKIs targeting other NSCLC oncogenic drivers (median PFS is 2.3 months, and median OS is 6.8 months) [115]. The gene discussed is RET; the disease is lung carcinoma.